# Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

> **NCT02654990** · PHASE2 · COMPLETED · sponsor: **pharmaand GmbH** · enrollment: 248 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Panobinostat Capsules
- **DRUG:** Bortezomib Injection
- **DRUG:** Dexamethasone tablets

## Key facts

- **NCT ID:** NCT02654990
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-27
- **Primary completion:** 2019-10-18
- **Final completion:** 2022-08-15
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02654990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02654990, "Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02654990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*